Physician profile
Benjamin Abraham
NPI 1538156542
$19,609.38
in general payments reported to CMS, 2019-2025
61 companies · $3,302 in 2025
The $3,302 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,305 · 2020: $1,955 · 2021: $4,181 · 2022: $2,222 · 2023: $2,671 · 2024: $2,974 · 2025: $3,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,848 · Education: $98.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,848.35 |
| Education | $98.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,160.24 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $1,722.44 | 2019-2024 | Xarelto |
| Amgen INC. | $1,711.52 | 2019-2025 | Repatha, Evenity, Otezla |
| Biohaven Pharmaceuticals, INC. | $1,607.64 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $1,257.00 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $1,008.31 | 2021-2025 | |
| Glaxosmithkline, LLC. | $869.42 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $764.60 | 2019-2025 | Mounjaro, Jardiance, Amyvid |
| Astellas Pharma US INC | $758.90 | 2019-2025 | Veozah |
| Pfizer INC. | $724.23 | 2019-2025 | |
| Novo Nordisk INC | $516.71 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.66 | 2019-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $494.28 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $454.23 | 2021-2025 | Rexulti |
| Esperion Therapeutics, INC. | $451.48 | 2020-2025 | Nexletol |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.